Conatus Pharmaceuticals

Emricasan™, a caspase inhibitor for liver diseases

The founding team of Conatus re-acquired Emricasan™, a caspase inhibitor for reducing apoptosis and inflammation in the treatment of liver diseases. Emricasan™ is a hepatoprotectant arresting the rate of deterioration of liver function. It is in several Phase II clinical studies for a number of liver diseases.

CEO  Steven J. Mento

Advent Contact  Shahzad Malik

Advent invested in the Series A in 2006. Conatus listed on NASDAQ in 2013 (NASDAQ:CNAT).
Exited Investments
25 July 2013 in Conatus Pharmaceuticals, Press Release

Conatus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

Press Release.   San Diego, CA – July 25, 2013 – Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease,…
Read More
31 March 2011 in Conatus Pharmaceuticals, Press Release

Conatus CTS-1027

Press Release.   SAN DIEGO, March 31, 2011 — Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and…
Read More